plerixafor sold brand name mozobil immunostimulant used mobilize hematopoietic stem cells cancer patients bloodstream stem cells extracted blood transplanted back patient drug developed anormed subsequently bought genzyme peripheral blood stem cell mobilization important source hematopoietic stem cells transplantation generally performed using granulocyte colonystimulating factor gcsf ineffective around patients combination gcsf plerixafor increases percentage persons respond therapy produce enough stem cells drug approved patients lymphoma multiple phase clinical trials started exploring combination plerixafor studies pregnant animals shown teratogenic effects plerixafor therefore contraindicated pregnant women except critical cases fertile women required use contraception known whether drug secreted breast milk breast feeding discontinued nausea diarrhea local reactions observed patients problems digestion general symptoms like dizziness headache muscular pain also relatively common found patients allergies occur less cases adverse effects clinical trials mild european medicines agency listed number safety concerns evaluated postmarketing basis notably theoretical possibilities spleen rupture tumor cell mobilisation first concern raised splenomegaly observed animal studies gcsf cause spleen rupture rare cases mobilisation tumor cells occurred patients leukaemia treated interaction studies conducted fact plerixafor interact cytochrome system indicates low potential interactions form zinc complex plerixafor acts antagonist perhaps accurately partial agonist alpha chemokine receptor allosteric agonist alphachemokine receptor one ligands important hematopoietic stem cell homing bone marrow hematopoietic stem cell quiescence vivo effect plerixafor regard ubiquitin alternative endogenous ligand unknown plerixafor found strong inducer mobilization hematopoietic stem cells bone marrow bloodstream peripheral blood stem additionally plerixafor inhibits expression b cells interfering axis regulates expressioncitation needed following subcutaneous injection plerixafor absorbed quickly peak concentrations reached minutes bound plasma proteins rest mostly resides extravascular compartments drug metabolized significant amounts interaction cytochrome enzymes pglycoproteins found plasma half life hours plerixafor excreted via kidneys drug excreted within plerixafor macrocyclic compound bicyclam derivative cyclam rings linked amine nitrogen atoms base eight nitrogen atoms accept protons readily two macrocyclic rings form chelate complexes bivalent metal ions especially zinc copper nickel well cobalt rhodium biologically active form plerixafor zinc three four nitrogen atoms macrocycle cyclam protected tosyl groups product treated potassium carbonate acetonitrile cleaving tosyl groups hydrobromic acid plerixafor octahydrobromide molecule first synthesised carry basic studies redox chemistry dimetallic coordination serendipitously discovered another chemist molecule could potential use treatment hiv role blocking chemokine receptor acts coreceptor certain strains hiv along viruss main cellular receptor development indication terminated lacking oral availability cardiac disturbances studies led new indication cancer plerixafor orphan drug status united states european union mobilization hematopoietic stem cells approved us food drug administration fda indication december european union drug approved positive committee medicinal products human use assessment report may drug approved use canada health canada december plerixafor seen reduce metastasis mice several also shown reduce recurrence glioblastoma mouse model radiotherapy model cancer cells survived radiation critically depended bone marrow derived cells vasculogenesis recruitment latter mediated interactions blocked researchers imperial college demonstrated plerixafor combination vascular endothelial growth factor vegf mobilise mesenchymal stem cells endothelial progenitor cells peripheral blood randomized trial stem cell mobilization plerixafor improve healing ischemic diabetic blockade signalling plerixafor also unexpectedly found effective counteracting opioidinduced hyperalgesia produced chronic treatment morphine though animal studies conducted httpsenwikipediaorgwikiplerixafor